Premium
Ezetimibe Inhibits Expression of Acid Sphingomyelinase in Liver and Intestine
Author(s) -
Cheng Yajun,
Liu Fuli,
Wu Jun,
Zhang Yao,
Nilsson Åke,
Duan RuiDong
Publication year - 2009
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/s11745-009-3343-1
Subject(s) - ezetimibe , sphingomyelin , hep g2 , chemistry , cholesterol , small intestine , biochemistry , large intestine , medicine , pharmacology , endocrinology , biology , in vitro
Abstract Ezetimibe inhibits cholesterol absorption in the intestine. Sphingomyelin has strong interactions with cholesterol. We investigated the effects of ezetimibe on Sphingomyelinase (SMase) expression in intestine and liver. After feeding rats with ezetimibe (5 mg/kg per day) for 14 days, acid SMase activities in the liver and in the proximal part of small intestine were reduced by 34 and 25%, respectively. Alkaline SMase (alk‐SMase) was increased in the proximal part of the small intestine. Administration of lower doses of ezetimibe reduced acid SMase only in the liver by 14% ( P < 0.05). In cell culture studies, ezetimibe decreased acid SMase activity in Hep G2 and Caco‐2 cells dose‐dependently. The reductions were more rapid for Hep G2 cells than for Caco‐2 cells. Western blot showed that acid SMase protein was decreased in both Hep G2 and Caco‐2 cells by 100 μM ezetimibe. The SM content was increased in Hep G2 cells but not Caco‐2 cells, and total cholesterol content was increased in both cell lines 24 h after stimulation with 100 μM ezetimibe. Mevastatin, the inhibitor of cholesterol synthesis, induced a mild increase in acid SMase activity in Hep G2 cells but not Caco‐2 cells. Following the reduction of acid SMase, ezetimibe at high dose slightly increased alk‐SMase activity. In conclusion, the study demonstrates an inhibitory effect of ezetimibe on acid SMase activity and expression in both liver and intestine.